--- Bacillus Calmette-Guerin (BCG) is the standard of care for intravesical therapy for carcinoma in situ and non-muscle invasive, non-metastatic human urothelial carcinoma. Although the responsiveness to this immunotherapeutic is believed to be linked wi

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010970-09
Application #
9343754
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Vandeveer, Amanda J; Fallon, Jonathan K; Tighe, Robert et al. (2016) Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res 4:452-62
Fallon, Jonathan; Tighe, Robert; Kradjian, Giorgio et al. (2014) The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 5:1869-84
Tucker, Jo A; Jochems, Caroline; Boyerinas, Benjamin et al. (2014) Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunol Immunother 63:1307-17
Schlom, Jeffrey; Hodge, James W; Palena, Claudia et al. (2014) Therapeutic cancer vaccines. Adv Cancer Res 121:67-124
Takai, Shinji; Schlom, Jeffrey; Tucker, Joanne et al. (2013) Inhibition of TGF-?1 signaling promotes central memory T cell differentiation. J Immunol 191:2299-307
Takai, Shinji; Sabzevari, Helen; Farsaci, Benedetto et al. (2012) Distinct effects of saracatinib on memory CD8+ T cell differentiation. J Immunol 188:4323-33
Bonmassar, Laura; Fossile, Emanuela; Scoppola, Alessandro et al. (2010) Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. Anticancer Res 30:4721-30
Hance, Kenneth W; Rogers, Connie J; Zaharoff, David A et al. (2009) The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines. Clin Cancer Res 15:2387-96
Wansley, Elizabeth K; Chakraborty, Mala; Hance, Kenneth W et al. (2008) Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 14:4316-25
Zeytin, Hasan; Reali, Eva; Zaharoff, David A et al. (2008) Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity. J Interferon Cytokine Res 28:73-87